The impact of combined liposomal bupivacaine-induced TAPB and RSB under appropriate anesthesia depth on cognitive function and recovery quality in elderly patients undergoing colorectal cancer surgery

The impact of combined liposomal bupivacaine-induced TAPB and RSB under appropriate anesthesia depth on cognitive function and recovery quality in elderly patients undergoing colorectal cancer surgery - The impact of combined liposomal bupivacaine-induced TAPB and RSB under appropriate anesthesia depth on cognitive function in elderly patients undergoing colorectal cancer surgery

Status

Active, not recruiting

Phases

Phase 4

Study type

Interventional

Source

ChiCTR

Registry ID

ChiCTR2500109317

Enrollment

Unknown

Registered

2025-09-16

Start date

2025-09-20

Completion date

Unknown

Last updated

2025-09-22

For informational purposes only — not medical advice. Sourced from public registries and may not reflect the latest updates. Terms

Conditions

Colorectal cancer

Interventions

Bupivacaine Hydrochloride Group (Group B):A 40ml standard solution of 0.25% bupivacaine was used for TAPB+RSB

Bupivacaine liposome group (L group):Prepared bicarbonate liposome 266mg diluted to 40ml for TAPB+RSB

Bupivacaine liposome + bupivacaine hydrochloride mixture group (Group M):0.25% bupivacaine standard solution + 266mg bupivacaine liposome, and the mixture of both is 40ml for TAPB+RSB

Eligibility

Sex/Gender

All

Age

60 Years to 74 Years

Inclusion criteria

Inclusion criteria: 1. Aged >= 65 and = 24 on the day before surgery. 5. Good limb mobility, auditory comprehension, and verbal expression abilities. 6. No recent use of opioid analgesics or antipsychotic medications. 7. Informed of the study details and provided consent to participate.

Exclusion criteria

Exclusion criteria: 1. Contraindications to TAPB and RSB performance; including but not limited to: coagulation disorders, infection at the puncture site or systemic severe infection, known allergy to local anesthetics. 2. Pre-existing severe comorbid diseases of the cardiovascular, pulmonary, hepatic, renal, hematological, or immune systems. 3. Pre-existing severe cardiac arrhythmias, such as severe bradycardia or atrioventricular block. 4. Patients for whom the TAPB and/or RSB procedure is unsuccessful (e.g., due to technical difficulties or inadequate block spread as assessed by sensory testing).

Design outcomes

Primary

Measure	Time frame
S-100ß;NSE;MMSE;QoR-15;	—

Countries

China

Contacts

Public ContactZhan Xi

The First Affiliated Hospital of Kunming Medical University

2489555365@qq.com+86 136 9870 5939

Outcome results

None listed

Source: ChiCTR (via WHO ICTRP) · Data processed: Feb 4, 2026